Methyl α-Linolenyl Fluorophosphonate
(Synonyms: MLnFP) 目录号 : GC13953
A phospholipase inhibitor
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Methyl α-Linolenyl Fluorophosphonate is an inhibitor of phospholipases.
Methyl α-linolenyl fluorophosphonate (MLnFP), an analog of methyl arachidonyl fluorophosphonate (MAFP), has not been completely investigated for its pharmacological activity.
In vitro: Methyl arachidonyl fluorophosphonate (MAFP) was reported to be a selective, active-site directed, irreversible inhibitor of cytosolic phospholipase A2 (cPLA2). MAFP could also potently inhibit the Ca2+-independent cytosolic phospholipase A2 (iPLA2) in a concentration-dependent manner. Such inhibition was not reversed upon extensive dilution of the enzyme into the assay mixture. Preincubation of iPLA2 with MAFP led to a linear and time-dependent inactivation of enzyme activity, and the enzyme was protected from inactivation by the reversible inhibitor. The ability of MAFP to inhibit the iPLA 2 indicated that this enzyme proceeded via an acyl-enzyme intermediate. Further testing showed that MAFP could not inhibit the CoA-dependent acyltransferase, arachidonoyI-CoA synthetase, or CoA-independent transacylase activities. Therefore, MAFP was not a general inhibitor for enzymes acting on arachidonoyi substrates [1].
In vivo: Up to now, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Lio, Y. C.,Reynolds, L.J.,Balsinde, J., et al. Irreversible inhibition of Ca2+-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. Biochimica et Biophysica Acta 1302, 55-60 (1996).
| Cas No. | SDF | ||
| 别名 | MLnFP | ||
| 化学名 | 9Z,12Z,15Z-octadecatrienyl-phosphonofluoridic acid, methyl ester | ||
| Canonical SMILES | CC/C=C\C/C=C\C/C=C\CCCCCCCCP(=O)(F)OC | ||
| 分子式 | C19H34FO2P | 分子量 | 344.4 |
| 溶解度 | ≤5mg/ml in ethanol;5mg/ml in DMSO;5mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9036 mL | 14.518 mL | 29.036 mL |
| 5 mM | 0.5807 mL | 2.9036 mL | 5.8072 mL |
| 10 mM | 0.2904 mL | 1.4518 mL | 2.9036 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。